Heidi Roschitzki-Voser
www.IBCSG.org
0000-0002-5432-2385
International Breast Cancer Study Group (IBCSG) and European Thoracic Oncology Platform (ETOP)
2 papers found
Refreshing results…
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
Missing publications? Search for publications with a matching author name.